Thursday, August 18, 2022 8:09:04 AM
(PRNewsfoto/Curis, Inc.)
NEWS PROVIDED BY
Curis, Inc.
Aug 18, 2022, 08:00 ET
SHARE THIS ARTICLE
Curis working with clinical sites to resume enrollment
Preliminary clinical data update expected in 2023
LEXINGTON, Mass., Aug. 18, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the TakeAim Lymphoma Phase 1/2 study of emavusertib after reviewing the comprehensive data package submitted by Curis.
"We are excited to announce that FDA has completed its review of the TakeAim Lymphoma study and has lifted the partial clinical hold. We are working with our clinical sites to quickly resume enrollment of new patients in this study in the third quarter," said James Dentzer, President and Chief Executive Officer of Curis.
Previously, Curis announced that the FDA had placed separate partial clinical holds on the TakeAim Leukemia and TakeAim Lymphoma studies on April 4 and April 11, 2022, respectively. The partial hold on the TakeAim Leukemia study was issued by the FDA Division of Hematologic Malignancies 1 (DHM1), which regulates clinical studies in leukemia. The partial hold on the TakeAim Lymphoma study, and the lifting of that hold, was issued by the FDA Division of Hematologic Malignancies 2 (DHM2), which regulates clinical studies in lymphoma. The partial clinical hold was lifted following agreement with the FDA on Curis's strategy for rhabdomyolysis identification and management, as well as on the enrollment of at least nine additional patients at the 200 mg dose level of emavusertib in combination with ibrutinib.
With the partial clinical hold lifted on the TakeAim Lymphoma study, the Company is updating its timeline for clinical data release to reflect the availability of updated preliminary data from this study in 2023. In addition, Curis is proactively discussing the clinical plans for emavusertib, including alignment on optimal dose and development path, with DHM2 for the TakeAim Lymphoma study.
About Emavusertib (CA-4948)
Emavusertib is an IRAK4 kinase inhibitor and IRAK4 plays an essential role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in patients with cancer. TLRs and the IL-1R family signal through the adaptor protein MYD88, which results in the assembly and activation of IRAK4, initiating a signaling cascade that induces cytokine and survival factor expression mediated by the NF-?B protein complex. Additionally, third parties have recently discovered that the long form of IRAK4 (IRAK4-L) is oncogenic and preferentially expressed in over half of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The overexpression of IRAK4-L is believed to be driven by a variety of factors, including specific spliceosome mutations such as SF3B1 and U2AF1. In addition to inhibiting IRAK4, emavusertib was also designed to inhibit FLT3, a known oncologic driver, which may provide additional benefit in patients with AML and MDS.
About TakeAim Leukemia
The TakeAim Leukemia study (NCT04278768) is a Phase 1/2 open-label dose escalation, dose expansion clinical trial investigating emavusertib as a monotherapy and in combination with azacitidine or venetoclax in patients with relapsed or refractory (R/R) AML or high risk MDS. After dose escalation in both monotherapy and combination therapy to determine the recommended Phase 2 dose (RP2D), we plan to expand five cohorts: monotherapy in AML patients with spliceosome and FLT3 mutations, monotherapy in patients with MDS and spliceosome mutations and combination therapy with azacitidine or venetoclax in patients without spliceosome or FLT3 mutations. The goals of the study are to determine several parameters including safety, maximum tolerated dose (MTD), RP2D and signals of activity.
About TakeAim Lymphoma
Recent CRIS News
- Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024 • PR Newswire (US) • 04/30/2024 12:00:00 PM
- Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 04/05/2024 11:30:00 AM
- Curis to Present at Upcoming Healthcare Conferences in April • PR Newswire (US) • 04/04/2024 11:30:00 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/12/2024 09:16:14 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/08/2024 09:36:50 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/08/2024 09:27:47 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/08/2024 09:01:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 01:01:02 PM
- Curis Provides Fourth Quarter 2023 Business Update • PR Newswire (US) • 02/08/2024 01:00:00 PM
- Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024 • PR Newswire (US) • 02/01/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 01:13:35 PM
- Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 01/05/2024 01:00:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 12/21/2023 09:00:47 PM
- Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study • PR Newswire (US) • 12/12/2023 01:00:00 PM
- Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference • PR Newswire (US) • 12/11/2023 01:00:00 PM
- Curis Announces Three Presentations at ASH • PR Newswire (US) • 12/06/2023 01:00:00 PM
- Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma • PR Newswire (US) • 12/05/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/02/2023 12:03:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 12:01:51 PM
- Curis Provides Third Quarter 2023 Business Update • PR Newswire (US) • 11/02/2023 12:00:00 PM
- Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023 • PR Newswire (US) • 10/26/2023 12:30:00 PM
- Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 10/06/2023 12:56:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 09/28/2023 08:05:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/28/2023 12:54:37 PM
- Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer • PR Newswire (US) • 09/12/2023 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM